6 news items
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
BLRX
6 May 24
% to 75% of patients required more than one apheresis session to collect a target number of cells.2,3
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
BLRX
17 Apr 24
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
BLRX
17 Apr 24
regimens and mobilization strategies, approximately 50% to 75% of patients required more than one apheresis session to collect a target number
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
BLRX
26 Mar 24
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
BLRX
29 Feb 24
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.
28aauhmn0zw1 38qlkjmoa6kq8y8a40zgf5ctiy0
BLRX
28 Feb 24
Motixafortide inhibits CXCR4, a chemokine receptor and a well validated therapeutic target that is over-expressed in many human cancers
- Prev
- 1
- Next